Search by Drug Name or NDC
NDC 42291-0679-50 Potassium Chloride 750 mg/1 Details
Potassium Chloride 750 mg/1
Potassium Chloride is a ORAL CAPSULE, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AvKARE. The primary component is POTASSIUM CHLORIDE.
MedlinePlus Drug Summary
Potassium is essential for the proper functioning of the heart, kidneys, muscles, nerves, and digestive system. Usually the food you eat supplies all of the potassium you need. However, certain diseases (e.g., kidney disease and gastrointestinal disease with vomiting and diarrhea) and drugs, especially diuretics ('water pills'), remove potassium from the body. Potassium supplements are taken to replace potassium losses and prevent potassium deficiency. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Related Packages: 42291-0679-50Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Potassium
Product Information
| NDC | 42291-0679 |
|---|---|
| Product ID | 42291-679_d57ed5a6-e031-4c8f-e053-2995a90a2bdb |
| Associated GPIs | 79700030000210 |
| GCN Sequence Number | 001248 |
| GCN Sequence Number Description | potassium chloride CAPSULE ER 10 MEQ ORAL |
| HIC3 | C1D |
| HIC3 Description | POTASSIUM REPLACEMENT |
| GCN | 03321 |
| HICL Sequence Number | 000549 |
| HICL Sequence Number Description | POTASSIUM CHLORIDE |
| Brand/Generic | Generic |
| Proprietary Name | Potassium Chloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Potassium Chloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 750 |
| Active Ingredient Units | mg/1 |
| Substance Name | POTASSIUM CHLORIDE |
| Labeler Name | AvKARE |
| Pharmaceutical Class | Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Salt [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA077419 |
| Listing Certified Through | 2024-12-31 |
Package
Package Images
NDC 42291-0679-50 (42291067950)
| NDC Package Code | 42291-679-50 |
|---|---|
| Billing NDC | 42291067950 |
| Package | 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (42291-679-50) |
| Marketing Start Date | 2013-03-05 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL 755a4a08-04ff-d7d1-a6fc-b8aeff3ae2c6 Details
DESCRIPTION:
Potassium Chloride Extended-release Capsules USP, 8 mEq and 10 mEq are oral dosage forms of
microencapsulated potassium chloride containing 600 mg and 750 mg of potassium chloride, USP
equivalent to 8 mEq and 10 mEq of potassium, respectively.
Dispersibility of potassium chloride (KCl) is accomplished by microencapsulation and a dispersing
agent. The resultant flow characteristics of the KCl microcapsules and the controlled release of K+
ions by the microcapsular membrane are intended to avoid the possibility that excessive amounts of KCl
can be localized at any point on the mucosa of the gastrointestinal tract.
Each crystal of KCl is microencapsulated by a process with an insoluble polymeric coating which
functions as a semi-permeable membrane; it allows for the controlled release of potassium and chloride
ions over an eight-to-ten-hour period. Fluids pass through the membrane and gradually dissolve the
potassium chloride within the micro-capsules. The resulting potassium chloride solution slowly
diffuses outward through the membrane. Potassium Chloride Extended-release Capsules, USP, 8 mEq
and 10 mEq are electrolyte replenishers.
The chemical name of the active ingredient is potassium chloride and the structural formula is KCl. It
has a molecular mass of 74.55. Potassium chloride, USP occurs as a white granular powder or as
colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely
soluble in water and insoluble in alcohol.
The inactive ingredients are, ethylcellulose, FD&C blue #1, FD&C red # 40, gelatin, sodium lauryl
sulfate, titanium oxide and triacetin.
CLINICAL PHARMACOLOGY:
12.1 Mechanis m of Action
The potassium ion (K+) is the principal intracellular cation of most body tissues. Potassium ions
participate in a number of essential physiological processes, including the maintenance of intracellular
tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and
the maintenance of normal renal function.
The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal
adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient
across the plasma membrane.
Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium
absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary
intake of potassium is 50 to 100 mEq per day.
12.3 Pharmacokinetics
Each crystal of KCl is microencapsulated and allows for the controlled release of potassium and
chloride ions over an eight- to ten-hour period.
Specific Populations
Cirrhotics
Based on publish literature, the baseline corrected serum concentrations of potassium measured over 3
hours after administration in cirrhotic subjects who received an oral potassium load rose to
approximately twice that of normal subjects who received the same load.
INDICATIONS AND USAGE:
CONTRAINDICATIONS:
WARNINGS:
Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the
gastrointestinal tract, particularly if the drug is in contact with the gastrointestinal mucosa for a
prolonged period of time. Consider the use of liquid potassium in patients with dysphagia, swallowing
disorders, or severe gastrointestinal motility disorders.
If severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs, discontinue
potassium chloride extended-release capsules and consider possibility of ulceration, obstruction or
perforation.
Potassium chloride extended-release capsules should not be taken on an empty stomach because of its
potential for gastric irritation [see Dosage and Administration (2.1)].
PRECAUTIONS:
General The diagnosis of potassium depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium, while acute acidosis per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.
Information For Patients
Physicians should consider reminding the patient of the following: To take each dose with meals and with a full glass of water or other suitable liquid. To take each dose without crushing, chewing, or sucking the capsules. To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations. To check with the physician if there is trouble swallowing capsules or if the capsules seem to stick in the throat.
To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.
Laboratory Tests Regular serum potassium determinations are recommended, especially in patients with renal insufficiency or diabetic nephropathy. When blood is drawn for analysis of plasma potassium it is important to recognize that artifactual elevations can occur after improper venipuncture technique or as a result of in vitro hemolysis of the sample.
Drug Interactions Potassium-sparing diuretics, angiotensin converting enzyme inhibitors (see WARNINGS).
Carcinogenesis, mutagenesis, impairment of fertility Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.
There are no human data related to use of potassium chloride extended-release capsules during
pregnancy and animal reproductive studies have not been conducted. Potassium supplementation that
does not lead to hyperkalemia is not expected to cause fetal harm.
The background risk for major birth defects and miscarriage in the indicated population is unknown. All
pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general
population, the estimated background risk of major birth defects and miscarriage in clinically
recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium
becomes part of the body potassium pool, as long as body potassium is not excessive, the contribution
of potassium chloride supplementation should have little or no effect on the level in human milk.
Clinical trial data from published literature have demonstrated the safety and effectiveness of potassium
chloride in children with diarrhea and malnutrition from birth to 18 years.
Clinical studies of potassium chloride did not include sufficient numbers of subjects aged 65 and over
to determine whether they respond differently from younger subjects. Other reported clinical
experience has not identified differences in responses between the elderly and younger patients. In
general, dose selection for an elderly patient should be cautious, usually starting at the low end of the
dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of
concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug
may be greater in patients with impaired renal function. Because elderly patients are more likely to have
decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal
function.
ADVERSE REACTIONS:
The following adverse reactions have been identified with use of oral potassium salts. Because these
reactions are reported voluntarily from a population of uncertain size, it is not always possible to
reliably estimate their frequency or establish a causal relationship to drug exposure.
The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal
pain/discomfort, and diarrhea.
There have been reports of hyperkalemia and of upper and lower gastrointestinal conditions including,
obstruction, bleeding, ulceration, and perforation.
Skin rash has been reported rarely.
To report SUSPECTED ADVERSE REACTIONS contact AvKARE, Inc. at 1-855-361-3993; email
[email protected]; or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
OVERDOSAGE:
10.1 Symptoms
The administration of oral potassium salts to persons with normal excretory mechanisms for potassium
rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, potentially fatal
hyperkalemia can result.
Hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium
concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves,
loss of P-waves, depression of S-T segment, and prolongation of the QT-interval). Late manifestations
include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).
10.2 Treatment
Treatment measures for hyperkalemia include the following:
1. Monitor closely for arrhythmias and electrolyte changes.
2. Eliminate foods and medications containing potassium and any agents with potassium-sparing
properties such as potassium-sparing diuretics, ARBs, ACE inhibitors, NSAIDs, certain nutritional
supplements, and many others.
3. Administer intravenous calcium gluconate if the patient is at no risk or low risk of developing
digitalis toxicity.
4. Administer 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline
insulin per 1,000 mL.
5. Correct acidosis, if present, with intravenous sodium bicarbonate.
6. Use exchange resins, hemodialysis, or peritoneal dialysis.
In patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium
concentration can produce digitalis toxicity.
The extended-release feature means that absorption and toxic effects may be delayed for hours.
Consider standard measures to remove any unabsorbed drug.
DOSAGE AND ADMINISTRATION:
2.1 Adminis tration and Monitoring
If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral
supplementation.
Monitoring
Monitor serum potassium and adjust dosages accordingly. Monitor serum potassium periodically during
maintenance therapy to ensure potassium remains in desired range.
The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or
acidosis requires careful attention to acid-base balance, volume status, electrolytes, including
Sections or subsections omitted from the full prescribing information are not listed.
magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms and the clinical status of the
patient. Correct volume status, acid-base balance and electrolyte deficits as appropriate.
Administration
Take with meals and with a full glass of water or other liquid. Do not take on an empty stomach because
of the potential for gastric irritation [see Warnings and Precautions (5.1)].
Patients who have difficulty swallowing capsules may sprinkle the contents of the capsule onto a
spoonful of soft food. The soft food, such as applesauce or pudding, should be swallowed immediately
without chewing and followed with a glass of water or juice to ensure complete swallowing of the
microcapsules. Do not added to hot foods. Any microcapsule/food mixture should be used immediately
and not stored for future use.
2.2 Adult Dos ing
Dosage must be adjusted to the individual needs of each patient. Dosages greater than 40 mEq per day
should be divided such that no more than 40 mEq is given in a single dose.
Treatment of hypokalemia:Typical dose range is 40 to 100 mEq per day.
Maintenance or Prophylaxis:Typical dose is 20 mEq per day.
2.3 Pediatric Dos ing
Pediatric patients aged birth to 16 years old: Dosage must be adjusted to the individual needs of each
patient. Do not exceed as a single dose 1 mEq/kg or 20 mEq, whichever is lower.
Treatment of hypokalemia: The recommended initial dose is 2 to 4 mEq/kg/day in divided doses. If
deficits are severe or ongoing losses are great, consider intravenous therapy.
Maintenance or Prophylaxis: Typical dose is 1 mEq/kg/day.
HOW SUPPLIED:
Potassium Chloride Extended-release Capsules, USP, 8 mEq are white opaque capsules, imprinted with Andrx logo on the cap and 559 on the body, each containing 600mg microencapsulated potassium chloride (equivalent to 8 mEq K) in bottles of 90 (NDC 42291-678-90).
Potassium Chloride Extended-release Capsules, USP, 10 mEq are dark blue opaque capsules, imprinted with Andrx logo on the cap and 560 on the body, each containing 750 mg microencapsulated potassium chloride (equivalent to 10 mEq K) in bottles of 90 (42291-679-90), bottles of 500 (42291-679-50).
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Dispense in a tight container as defined in the USP.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
Mfg. Rev. 02/15
AV Rev. 03/16 (P)
INGREDIENTS AND APPEARANCE
| POTASSIUM CHLORIDE
potassium chloride capsule, extended release |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
| POTASSIUM CHLORIDE
potassium chloride capsule, extended release |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
| Labeler - AvKARE (796560394) |